Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Atreca (BCEL) Gets a Buy Rating from Canaccord Genuity - Markets
10:06am, Tuesday, 16'th Jun 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL – Research Report) today and set a price
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Global Blood Therapeutics (GBT –
Alliancebernstein L.P. Has $38.43 Million Stake in Allogene Therapeutics Inc (NASDAQ:ALLO)
07:32am, Monday, 15'th Jun 2020
Alliancebernstein L.P. lifted its holdings in Allogene Therapeutics Inc (NASDAQ:ALLO) by 11.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange C
Top Insider Buys Highlight for the Week of June 12
03:38pm, Sunday, 14'th Jun 2020
The largest Insider Buys this week were for Keurig Dr Pepper Inc., CME Group Inc., Allogene Therapeutics Inc. and Old Republic International Corp. Continue reading...
4 Biotech Stocks That Are Seeing Big Buys in June
11:00am, Sunday, 14'th Jun 2020
Allogene Therapeutics, Personalis, Cortexyme, and La Jolla Pharmaceutical have all seen large stock purchases by insiders and big investors this month.
Analysts' Top Healthcare Picks: Regeneron (REGN), IMARA (IMRA) - Markets
03:44pm, Friday, 12'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN
Has Allogene Therapeutics (ALLO) Outpaced Other Medical Stocks This Year?
03:30pm, Wednesday, 10'th Jun 2020
Is (ALLO) Outperforming Other Medical Stocks This Year?
Les valeurs à suivre aujourd'hui à la Bourse de Paris Mercredi 10 juin 2020
07:01am, Wednesday, 10'th Jun 2020Swiss National Bank Boosts Position in Allogene Therapeutics Inc (NASDAQ:ALLO)
04:44am, Wednesday, 10'th Jun 2020
Swiss National Bank raised its stake in Allogene Therapeutics Inc (NASDAQ:ALLO) by 1.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Comm
Celyad devient Celyad Oncology
12:00am, Wednesday, 10'th Jun 2020
Regulatory News: Celyad SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), une société biotechnologique de stade clinique fo
Insider Weekends: A Large Sale By The CEO Of An Airline
12:29pm, Monday, 08'th Jun 2020
Insider buying decreased last week. Notable Insider Buys: Danaher Corporation, Avid Technology, Inc., Allogene Therapeutics, Inc., La Jolla Pharmaceutical Compa
Xconomy: Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More
03:33pm, Friday, 05'th Jun 2020
Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic
Why Is Allogene Therapeutics (ALLO) Up 40.6% Since Last Earnings Report?
03:32pm, Friday, 05'th Jun 2020
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
12:30pm, Wednesday, 03'rd Jun 2020
SOUTH SAN FRANCISCO, Calif., June 03, 2020 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T.
Allogene Seeks To Raise $550 Million From Share Sale Priced At $47
11:14am, Tuesday, 02'nd Jun 2020
Allogene Therapeutics Inc. (ALLO) is seeking to raise $550 million from an underwritten public offering of 11,702,128 shares of its common stock.The biotech company is making the offering at a price t
